

# Mark T Jennings

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/751625/publications.pdf>

Version: 2024-02-01

12  
papers

2,992  
citations

933447

10  
h-index

1281871

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

5507  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low rates of macrolide-resistant <i>Mycobacterium avium</i> complex in cystic fibrosis despite chronic azithromycin therapy. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 555-557.	0.7	0
2	Takotsubo Syndrome in the Setting of COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 1321-1325.	0.6	122
3	Eradication of persistent methicillin-resistant <i>Staphylococcus aureus</i> infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 357-363.	0.7	35
4	Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis. <i>Pancreatology</i> , 2019, 19, 1023-1026.	1.1	33
5	Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections. <i>Respirology</i> , 2018, 23, 628-635.	2.3	3
6	Risk factors for persistent <i>Aspergillus</i> respiratory isolation in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 624-630.	0.7	43
7	Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant <i>Staphylococcus aureus</i> in cystic fibrosis patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 296-299.	1.8	26
8	Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. <i>Annals of the American Thoracic Society</i> , 2018, 15, 897-902.	3.2	19
9	An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1662-1666.	3.2	59
10	Risk factors for persistent methicillin-resistant <i>Staphylococcus aureus</i> infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 681-686.	0.7	28
11	Eradication strategy for persistent methicillin-resistant <i>Staphylococcus aureus</i> infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 223.	1.6	21
12	Update on Key Emerging Challenges in Cystic Fibrosis. <i>Medical Principles and Practice</i> , 2014, 23, 393-402.	2.4	2,603